Pulmonx Corp reported results for the 2026 quarter with revenue of $22.76M and a net loss of ($10.08M), or diluted EPS of ($0.24), representing improvement versus the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$22.76M$23.86M(4.6%) | Net income²($10.08M)($15.17M)33.6% | Diluted EPS³($0.24)($0.38)36.8% |
¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share attributable to common stockholders, basic and diluted”.
Business Highlights
- Revenue trend: Procedure volumes declined, driving a roughly 5%–7% year‑over‑year revenue decline across the quarter and year‑to‑date, with notable softness in the U.S. and China awaiting registration renewal earlier in the period.
- Gross margin and mix: Gross margin improved to about 78%, helped by a favorable geographic mix despite lower unit volumes.
- Commercial expansion: Continued U.S. direct‑sales focus across approximately 500 high‑volume hospitals; shipments to China resumed following registration renewal.
- Product and R&D: Ongoing investments in the Zephyr ecosystem, progress on the CONVERT II trial for AeriSeal, and efforts to drive adoption of LungTraX and Chartis tools.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.